Tag Archive for: small pharma

Psychedelic Stocks Compass Small Pharma Mydecine Awakn

A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial

,
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
5 Next-Generation Psychedelics Entering Clinical Trials This YearShutterstock

5 Next-Generation Psychedelics Entering Clinical Trials This Year

,
Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation psychedelics on the horizon.
5 Most Important Psychedelic Clinical Trials of 2022Shutterstock

5 Most Important Psychedelic Clinical Trials in 2022

Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Is Small Pharma a Good Psychedelic Stock Investment?Shutterstock

Is Small Pharma a Good Psychedelic Stock Investment?

,
Our resident Psychedelic Investor James Hallifax looks at the pros and cons of this Canadian-based company developing DMT for therapeutic use.
Psychedelic Business Spotlight March 11

Psychedelic Business Spotlight- March 11

,
This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves a psilocybin PTSD study.
Psychedelic Business Spotlight: October 22

Psychedelic Business Spotlight: October 22

,
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.
Psychedelic Business Spotlight: September 24, 2021

Psychedelic Business Spotlight: September 24, 2021

,
This week in psychedelic business news: two patents may revolutionize the medical application of psychedelic compounds; DMT and ibogaine clinical trials show promise; and stock news for psychedelic investors.